<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062346</url>
  </required_header>
  <id_info>
    <org_study_id>Bean ICRF clinical study</org_study_id>
    <nct_id>NCT02062346</nct_id>
  </id_info>
  <brief_title>Endothelin Antagonism in ANCA Vasculitis</brief_title>
  <official_title>The Vascular Effects of Endothelin Receptor Antagonism in Systemic Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with vasculitis commonly develop cardiovascular disease. The reasons for this are&#xD;
      not clear and is not adequately treated with current drugs. It is thus understand the reasons&#xD;
      why patients with vasculitis develop cardiovascular disease in order to develop new drugs to&#xD;
      reduced this risk.&#xD;
&#xD;
      Endothelin is a chemical produced by blood vessels that contributes to the development of&#xD;
      hypertension and cardiovascular disease Higher than normal levels of endothelin are seen in&#xD;
      patients with vasculitis but how this contributes to cardiovascular disease in patients with&#xD;
      vasculitis is not clear. By using drugs that block the effects of endothelin ('endothelin&#xD;
      receptor antagonists') the investigators can hopefully reduce the risk of cardiovascular&#xD;
      disease in patients with vasculitis. The purpose of the study is to ascertain if endothelin&#xD;
      receptor antagonists improve blood vessel function in patients with vasculitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vasculitis patients and healthy controls matched for age, sex will be enrolled into the&#xD;
      study. Patients will attend for 4 study days &gt;1 week apart, whereas controls will attend for&#xD;
      single day. Circulating Mφ and other immune cells will be confirmed using FACS prior each&#xD;
      study.&#xD;
&#xD;
      Study 1 Both patients and control will attend for visit 1: assessment of vascular function&#xD;
      using forearm plethysmography as part of case control study.&#xD;
&#xD;
      Vasculitis patients will then attend for visits 2, 3 &amp; 4 as part of randomised three way&#xD;
      crossover study (randomised &amp; infusions given in a double-blind method): comparison of the&#xD;
      effects of selective ETA receptor antagonism (BQ123; 1000nmol/min for 15min iv), mixed ETA/B&#xD;
      antagonism (BQ123/788; 1000 nmol/min &amp; 300 nmol/min for 15 min), and placebo on systemic&#xD;
      haemodynamics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study 1 - forearm blood flow</measure>
    <time_frame>20mins</time_frame>
    <description>Response to endothelium-dependent vasodilators</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study 2 - pulse wave velocity</measure>
    <time_frame>4 hours</time_frame>
    <description>Response of participants to ET antagonism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study 1 - tPA release</measure>
    <time_frame>20min</time_frame>
    <description>Response of fibrinolytic system to endothelial vasodilators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 1 - baseline pulse wave velocity</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline arterial stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study 2 - tPA release</measure>
    <time_frame>4 hours</time_frame>
    <description>Response of participants to ET antagonism</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Vasculitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BQ123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of BQ123 1000nmol/min for 15min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BQ123/788</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of BQ123 1000nmol/min and BQ788 300nmol/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Assessment of forearm vascular function</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Response of forearm blood flow to endothelium-dependent and endothelium-independent vasodilators</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ123</intervention_name>
    <description>Intravenous infusion of BQ123 ( selective ETA antagonist )</description>
    <arm_group_label>BQ123</arm_group_label>
    <other_name>Selective ETA antagonism</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ123/788</intervention_name>
    <description>or BQ123/788 (mixed ETA/B antagonists)</description>
    <arm_group_label>BQ123/788</arm_group_label>
    <other_name>mixed ETA/B antagonism</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion of saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age 18 years and over&#xD;
&#xD;
          -  Body mass index ≤35&#xD;
&#xD;
          -  Normal serum albumin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with diabetes or current smoking or chronic kidney disease (eGFR &lt;60ml/min)&#xD;
&#xD;
          -  Subject with pre-existing cardiovascular disease&#xD;
&#xD;
          -  Subject is below the age of legal consent, or is mentally or legally incapacitated&#xD;
&#xD;
          -  History of multiple and/or severe allergic reactions to drugs (including study drugs)&#xD;
&#xD;
          -  The subject has donated blood (450 ml) within the last 4 weeks&#xD;
&#xD;
          -  Past or present drug or alcohol abuse including intravenous drug abuse at any time&#xD;
&#xD;
          -  Participation in another clinical trial within 1 month&#xD;
&#xD;
          -  Considered to be at high risk of HIV or hepatitis B&#xD;
&#xD;
          -  Women of child-bearing potential (only women who are post-menopausal or&#xD;
             surgically-sterilised will be included in the study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeraj Dhaun</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Midlothian</state>
        <zip>EH16 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelin;</keyword>
  <keyword>blood pressure;</keyword>
  <keyword>vasculitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>cyclo(Trp-Asp-Pro-Val-Leu)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

